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Drug resistanceWhile the role of small non-coding RNAs, such as miRNAs, in apoptosis control is well established, long
non-coding RNAs (lncRNAs) have received less attention. Growth Arrest-Speciﬁc 5 (GAS5) encodes multiple
snoRNAs within its introns, while exonic sequences produce lncRNA which can act as a riborepressor of the
glucocorticoid and related receptors. GAS5 negatively regulates the survival of lymphoid and breast cells, and
is aberrantly expressed in several cancers. Although cellular GAS5 levels decline as prostate cancer cells acquire
castration-resistance, the inﬂuence of GAS5 on prostate cell survival has not been determined. To address this
question, prostate cell lines were transfected with GAS5-encoding plasmids or GAS5 siRNAs, and cell survival
was assessed. Basal apoptosis increased, and cell survival decreased, after transfection of 22Rv1 cells with plas-
mids encoding GAS5 transcripts, including mature GAS5 lncRNA. Similar effects were observed in PC-3 cells.
In stable clones of 22Rv1, cell death correlated strongly with cellular GAS5 levels. Induction of 22Rv1 cell
death by UV-C irradiation and chemotherapeutic drugs was augmented in cells transiently transfected
with GAS5 constructs, and attenuated following down-regulation of GAS5 expression. Again, in these ex-
periments, cell death was strongly correlated with cellular GAS5 levels. Thus, GAS5 promotes the apoptosis
of prostate cells, and exonic sequence, i.e.GAS5 lncRNA, is sufﬁcient tomediate this activity. Abnormally low
levels of GAS5 expression may therefore reduce the effectiveness of chemotherapeutic agents. Although several
lncRNAs have recently been shown to control cell survival, this is the ﬁrst report of a death-promoting lncRNA in
prostate cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Although a large portion of the human genome is transcribed,
protein coding genes account for b2% of genomic sequence [1,2]. Conse-
quently, the human transcriptome comprises largely of non-coding
RNAs (ncRNAs) and there is currently much interest in the roles of
such transcripts both in basic biology and in major pathologies such as
cancer [1–5]. The ncRNAs can be broadly divided into short ncRNAs
(typically up to 200 nucleotides in length) and long ncRNAs (lncRNAs;
from 200 nucleotides up to ca. 100 kb) [1,3]. The former subclass
includes tRNAs, certain rRNAs, snRNAs and snoRNAs, many of which
have house-keeping roles in protein synthesis, as well as miRNAs,
which are important regulators of gene expression [1,3,4,6]. Several
miRNAs [7–9] and,more recently, snoRNAs [5,10] have been implicated
both in cancer and in the control of apoptosis in mammalian cells. The
lncRNAs include well characterized ribosomal RNAs, and manye element; HNSCC, head and
A; ncRNA, non-coding RNA;
oligopyrimidine tract
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rights reserved.mRNA-like transcripts such as long intergenic ncRNAs, transcribed
ultraconserved regions and transcribed pseudogenes, as well as anti-
sense and intronic transcripts [1,3,11]. The vast majority of lncRNAs
remain to be functionally annotated, and even those characterized so
far have diverse cellular roles, including: structural scaffolds (e.g. in
nuclear substructures); chromatin modiﬁcation; and regulation of gene
expression at both the transcriptional and post-transcriptional levels
[1,3,11]. Most recently, several pieces of evidence have emerged linking
lncRNAs with cancer [3,11–13].
The lncRNA and snoRNA host gene, growth arrest-speciﬁc 5 (GAS5),
encoded at prostate cancer-associated locus 1q25 (e.g. [14]), is of par-
ticular interest in this regard. This gene was originally identiﬁed via
subtractive cDNA cloning of genes which are preferentially expressed
in growth-arrested cells [15]. GAS5 comprises 12 exons and encodes
ten box C/D snoRNAs within its introns [16]; three of these snoRNAs,
U44, U74 and U78, may also give rise to miRNAs [17]. Two mature
GAS5 lncRNAs have been identiﬁed in humans due to the presence
of alternative 5′-splice donor sites in exon 7 [16], and a multitude of
other ESTs have been identiﬁed, many of which contain retained
introns. The open reading frame encoded within GAS5 exons is short
and thought not to encode a functional protein. This, together with
the presence of a conserved 5′-terminal oligopyrimidine tract
(5′-TOP), explains why GAS5 ncRNA accumulates upon growth arrest
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12-derived sequence has been shown to structurally mimic the gluco-
corticoid receptor response element (GRE) and has been demonstrated
to act as a riborepressor of the glucocorticoid receptor [18]. Importantly
in the prostate context, these workers also showed that GAS5 mRNA
sequesters the androgen/androgen receptor complex and prevents
its binding to target DNA sequences [18]. Since GAS5 is ubiquitously
expressed on growth arrest, this inhibition of the androgen receptor
pathway is likely to play an important role in modulating the effects
of androgen on prostate cells.
Several lines of evidence implicate GAS5 ncRNA in other cancers. For
example, GAS5 and/or its snoRNAs have been shown to be aberrantly
expressed in breast cancer, head and neck squamous cell carcinoma
(HNSCC) and glioblastoma multiforme, where tumor expression is
reduced [19–21], and non-small-cell lung cancer (NSCLC), where
over-expression of the snoRNAs U44, U76 and U78 occurs [22]. For
breast cancer and HNSCC, lowGAS5 expression is an adverse prognostic
factor for survival [21]. Theseﬁndings are consistentwith the identiﬁca-
tion of GAS5 as a key regulator of lymphoid cell survival in a functional
cloning screen [23], and the subsequent demonstration that it regulates
cell proliferation/survival in human epithelial cell lines [18,20]. GAS5 is
induced in response to certain apoptotic stimuli [24,25] and, in the case
of the mTOR inhibitor rapamycin, it mediates the anti-proliferative/
pro-apoptotic effects of this drug on human T-cells [26,27]. Further-
more, forced variation of GAS5 gene expression can modulate cellular
responses to various apoptotic stimuli, including a range of chemother-
apeutic drugs [18,20], suggesting a mechanism linking dysregulated
GAS5 expression in cancer with patient prognosis.
We previously reported that GAS5 gene expression was reduced
in prostate cell lines derived from metastases (LNCaP and PC-3)
when compared with those derived from normal prostate or primary
prostate cancer (PNT2C2, P4E6 and 22Rv1) [20]. More recently,
down-regulation of GAS5 expression has been reported to be associ-
ated with the progression of LNCaP cells to castration-resistant prostate
cancer in an in vivo model [28]. Despite these ﬁndings, the inﬂuence
of GAS5 on prostate cell survival is currently unknown. Therefore, the
initial aim of this study was to investigate if GAS5 regulates apoptosis/
survival of prostate cancer cells, both under basal conditions and after
challenge with a range of cell death stimuli, including chemotherapeu-
tic agents. In view of the complex nature of the GAS5 gene, i.e., as both a
snoRNA host gene and lncRNA, the functional activity of GAS5 lncRNA
(i.e., exons alone) was speciﬁcally analyzed.
2. Material and methods
2.1. Material
The 22Rv1 and PC-3 parental cell lines were purchased from
ATCC-LGC Promochem (Teddington, Middlesex, UK) and cell culture
media and supplements were from Sigma-Aldrich Company Ltd
(Gillingham, UK) and Life Technologies Ltd (Paisley, UK). Ambion
Silencer Select siRNAs, reagents for RNA isolation and reverse transcrip-
tion and TaqMan assays were also from the latter source. The RQ1
RNase-free DNase was from Promega (Southampton, UK) and the
SensiFast Probe Hi-ROX kit was from Bioline (London, UK). RNAiFect
reagent was from Qiagen (Crawley, UK) and nucleofector solution V
was from Lonza Biosciences (Verviers, Belgium).
2.2. Methods
2.2.1. Cell culture
This study employed 22Rv1 clone 8 cells, which were previously
derived by soft agar cloning of the parental cell line and which display
uniform sensitivity to a range of apoptotic stimuli [29], and the PC-3 cell
line, which was used directly without subcloning. Culture medium for
22Rv1 clone 8 cells was RPMI-1640 supplemented with L-glutamine(2 mM), fetal bovine serum (10% (v/v) and gentamicin (50 μg/ml),
and for PC-3 cells was nutrient mix F-12 (Kaighn's modiﬁcation)
supplemented with fetal bovine serum (10% (v/v)) and gentamicin
(50 μg/ml). Both cell lines were cultured at 37 °C in a humidiﬁed incu-
bator with 5% CO2.
2.2.2. Plasmid DNA transfection
Plasmids containing GAS5 sequence were: pcDNA3/GAS5.O1,
which encodes the GAS5 O1 EST [20]; and pcDNA3/GAS5.AE, which
encodes mature GAS5 ncRNA, isoform GAS5b (exons 1–12, including
the long form of exon 7 [exon 7b]) [16]. The latter insert was ampli-
ﬁed from cDNA prepared from stationary phase NB4 cells (a human
myeloid leukemia cell line) by PCR using Pfu DNA polymerase and
the forward and reverse primers: GTTTCGAGGTAGGAGTCGACT and
GGATTGCAAAAATTTATTAAAATTG, tailed, then TOPO cloned. Empty
pcDNA3 vector was used as the control. Cells were transfected with
plasmids (2 μg per 2 × 106 cells in 0.1 ml nucleofector solution V) by
nucleofection, using programmes X-001 and T-013 for 22Rv1 clone 8
and PC-3 cells, respectively, and cells were then plated in 3 ml of the
appropriate culture medium in 6-well plates. Transfection efﬁciency,
determined in parallel transfections with pmaxGFP, was 71.0 ± 4.2%
(n = 5) for 22Rvl clone 8 cells and 68.5 ± 3.5% (n = 4) for PC-3 cells
at 20 h post-transfection.
For the production of stable clones, 22Rv1 clone 8 cells at 24 h
post-nucleofection were plated in 10 cm diameter tissue culture
plates in culture medium supplemented with 10% cell-conditioned
medium. After 24 h, the medium was replaced with fresh containing
0.8 mg/ml G418S, and cells were cultured in this cloning medium
(with twice-weekly medium changes) for 28 days. Well-separated col-
onies were then harvested using cloning cylinders and trypsinization,
cells were transferred to 24-well plates in cloning medium, and then
cultures were further expanded (with twice-weekly medium changes).
Once actively growing, clone stocks were routinely maintained in stan-
dard culture medium supplemented with 0.8 mg/ml G418S.
2.2.3. RNA interference by siRNA
22Rv1 clone 8 cells were plated in 6-well plates (4 × 105 cells/well).
After 24 h, medium was replaced with 1.9 ml fresh, then cells were
transfectedwith Ambion Silencer Select siRNAs to GAS5 using RNAiFect
reagent, according to the supplied standard protocol; the ﬁnal siRNA
concentration was 186 nM. Four different siRNAs were employed for
GAS5 knockdown; herein termed siRNAs #1–4; respective product
codes and targeted exons are: n272334/exon 2; n272337/exon 8;
n272340/exon 12 and n272331/exon 12 (distinct sequence from
siRNA#3), and controls were transfected with negative control (NC)
siRNA (code AM4611). Transfection efﬁciency, determined in parallel
transfections with Cy3-labelled NC siRNA, was 79.0 ± 4.0% (n = 3) at
72 h post-transfection.
2.2.4. Determination of apoptosis and cell survival in basal cells and after
treatment with inducers of cell death
At 20 h post-nucleofectionwith plasmids or at 72 h post-transfection
with siRNA, cells were harvested by trypsinization, a portion of cells was
removed for total RNA isolation, and the remaining cells resuspended at
105 cells/ml in fresh medium. They were seeded at 1.5 × 105 cells/well
(plasmid-transfected cells) or at 2.4 × 105 cells/well (siRNA-transfected
cells) of a 12-well plate. Prior to plating, a portion of cells was irradiated
with UV-C light in 35 mm diameter plastic Petri dishes using a UVG-54
hand-held lamp (UVP, Cambridge, UK); the dose administered was
20 J/m2 and thiswas veriﬁed using a Blak-RayUV (shortwave) intensity
meter (model J-225, UVP, Cambridge, UK). Immediately after UV
exposure (or mock irradiation for controls), cells were centrifuged,
resuspended in the same volume of fresh medium, then plated in
12-well dishes, as described above. For drug treatments, cells were
allowed to attach to plates for ≥8 h, then exposed to docetaxel
(6 nM), nutlin-3a (10 μM), mitoxantrone (200 nM) or vehicle (0.1%
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apoptotic stimuli, then adherent cells were trypsinized and combined
with non-adherent cells.
For functional assessment of stable clones, cells were seeded at
1.5 × 105 cells/well of a 12-well plate in standard culture medium
minus G418S and cells were harvested at 24 h for total RNA isolation
and at 72 h for assessment of apoptosis and culture growth.
Untransfected parental 22Rv1 clone 8 cells were also included in this
experiment. The experiment was performed a total of three times;
mean data only are reported here for the individual stable clones.
To determine short-term viability in transient and stable transfec-
tion experiments, cells were stained with nigrosin blue (0.1% (w/v))
and counted using a hemocytometer; cells which excluded the dye
were considered to be viable. For assessment of long-term survival,
cells were re-plated in culture medium supplemented with 10% (v/v)Fig. 1. Effect of GAS5 ncRNA on the basal survival of 22Rv1 clone 8 cells. Cells were transf
GAS5.O1 EST, or empty pcDNA3 vector as control. A). Cellular GAS5 levels, as determined by
constructs (n = 5). B). Total cell number at 72 h post-transfection is normal (n = 3). C). The
a similar extent in cells transfected with both GAS5 constructs at 72 h post-transfection (n =
with condensed or fragmented chromatin are indicated by arrows and arrowheads, respectiv
is reduced to a similar extent in cells transfected with both GAS5 constructs at 72 h post
cells is compromised after transfection with GAS5 ncRNA constructs (n = 4). An examp
bar chart (None = mock-transfected cells). In A, C, D & E: *P b 0.05 & **P b 0.01 versus cells trcell-conditioned medium in 6-well plates and the number of colonies
formed at 3 week culture was counted after staining with crystal violet
(0.5% (w/v) in methanol). Apoptosis was determined by assessment of
nuclear morphology by ﬂuorescence microscopy after staining with
acridine orange (25 μg/ml); cells containing condensed or fragmented
chromatin were considered as being apoptotic.
2.2.5. Real time RT-PCR
Total RNA was isolated using TRIZOL reagent, treated with RQ1
RNase-freeDNase, then reverse transcribed using randomhexamer prim-
ing and SuperScript II Reverse Transcriptase, according to the supplied
protocols. Real-time PCR was conducted using SensiFast Probe Hi-ROX
kit and TaqMan Gene Expression Assays (assay codes Hs99999901_m1
for 18S and Hs03464472_m1 for GAS5), as recommended by the man-
ufacturers, and was run on an ABI Prism Sequence Detection Systemected with GAS5 constructs corresponding to mature lncRNA (exons 1–12; AE) or the
RT-qPCR, are increased to a similar extent at 24 h post-transfection with the two GAS5
proportion of apoptotic cells, determined after acridine orange staining, is increased to
3). Example images of acridine orange-stained cells are shown below the bar chart; cells
ely; scale bar = 50 μm. D). Short-term viability, determined after nigrosin blue staining,
-transfection (n = 3). E). Clonogenic assay demonstrates that long-term survival of
le image of clonogenic assay plates after crystal violet staining is to the right of the
ansfected with pcDNA3 alone (one-way ANOVA and Bonferrroni's MCT).
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volume of 25 μl. A standard curve, comprising 0.2–60 ng cDNA
(prepared from untransfected 22Rv1 clone 8 cells) was included with
each run to allow relative quantitation. For each assay, a standard
curve of threshold cycle (CT) value versus log input standard cDNA
was constructed by linear regression, and the equation of the line was
used to calculate input amounts of samples from their respective CT
values. Data were expressed relative to 18S rRNA.
2.2.6. Statistical analyses
Data are presented as the mean and standard error of the mean
(SEM). For transient transfections, the number of observations (n) refers
to different transfected samples, each transfection being conducted on a
separate culture of cells, whereas for stable transfections, n refers to the
number of different clones. Data were analyzed either by an unpaired
Student's t-test (for comparison of two groups only) or by one-way
analysis of variance, using either Bonferroni's multiple comparison
test (MCT) or Dunnett's MCT (the latter when comparing multiple
groups versus a single group) for post-hoc analysis. Homogeneity of
variance was checked by Bartlett's test and, where necessary, data
were transformed (log or square root) prior to analysis. The relationship
between survival parameters and GAS5 levels in stable clones and inFig. 2. Effect of GAS5 ncRNA on the survival of 22Rv1 clone 8 cells after UV-C-induced apo
(exons 1–12; AE) or the GAS5.O1 EST, or empty pcDNA3 vector as control and, after 24 h, i
apoptosis, determined by acridine orange staining, at 48 h post-irradiation (n = 4). B). T
constructs increases UV-C induced loss of culture viability, determined by nigrosin blue st
irradation is compromised by prior transfection of cells with GAS5 ncRNA constructs (n =
below the bar chart. In A, C & D: *P b 0.05 & **P b 0.01 versus cells transfected with pcDNAsiRNA transfected cells was analyzed by linear regression. All statistical
analyses were performed using GraphPad Prism v4.03.3. Results
3.1. Transient expression of GAS5 enhances apoptosis and decreases the
survival of 22Rv1 cells
Two GAS5 constructs were studied here: i). GAS5 O1, comprising
the snoRNA U74, 3′ sequence of intron 1, and exons 2–12, which
has previously been shown to inﬂuence cell survival in breast and
kidney cell lines [20], and ii). GAS5 AE, comprising exons 1–12 only,
i.e., not encoding any of the snoRNAs. Nucleofection of 22Rv1 clone
8 cells with either of these constructs resulted in an approximate
4-fold increase in GAS5 transcript levels, when compared with cells
transfected with vector alone (Fig. 1A). Neither GAS5 construct had
any visible effect on total cell number (Fig. 1B), but each doubled
the basal apoptotic rate (Fig. 1C) and this was associated with reduc-
tions in short-term culture viability (Fig. 1D). Furthermore, the colony
forming ability of cultures transfected with each GAS5 construct was
approximately halved (Fig. 1E), conﬁrming that GAS5, including theptosis. Cells were transfected with GAS5 constructs corresponding to mature lncRNA
rradiated with UV-C light. A). Transfection of GAS5 constructs enhances UV-C induced
otal cell number at 48 h post-irradiation is normal (n = 4). C). Transfection of GAS5
aining of cells at 48 h post-irradiation (n = 4). D). Long term survival following UV-C
5). An example image of clonogenic assay plates after crystal violet staining is shown
3 alone (one-way ANOVA and Bonferrroni's MCT).
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22Rv1 clone 8 cells.
When cells were irradiated with UV-C light to induce apoptosis,
GAS5-transfected cells exhibited increased apoptosis relative to
vector-transfected cells; again the extent of apoptosis induction was
similar for the two GAS5 constructs (Fig. 2A). In a further experiment,
the pcDNA3/GAS5.AE construct was found to increase caspase activation
in 22Rv1 clone 8 cells, both under basal conditions and after irradiation
with UV-C light (Suppl. Fig. 1), independently conﬁrming the pro-
apoptotic activity of mature GAS5 lncRNA. Higher levels of apoptosis
were noted by assessment of caspase activation (Suppl. Fig. 1) when
compared with nuclear morphological changes (Figs. 1C and 2A),
consistent with differences in the time points post-transfection/UV
treatment used for these assays and the apoptotic events under evalua-
tion. While total cell number was unchanged following transfection
with GAS5 constructs (Fig. 2B), decreases in both short-term viability
(Fig. 2C) and long-term survival (Fig. 2D)were observed, with nodiffer-
ences again apparent between the two GAS5 constructs, conﬁrming
the functional importance of the GAS5 lncRNA. Notably the extent ofFig. 3. Effect of GAS5 ncRNA on the survival of 22Rv1 clone 8 cells after treatment with chem
ture lncRNA (exons 1–12; AE) or the GAS5.O1 EST, or empty pcDNA3 vector as control and
Cells were harvested after a further 48 h for determination of apoptosis (acridine orange s
hanced in cells transfected with GAS5 constructs. B). Nutlin-3a-induced apoptosis shows a s
following transfection with GAS5 constructs and docetaxel treatment. D). Short-term cultu
treatment. E). Total cell number is normal following transfection with GAS5 constructs a
GAS5 constructs and nutlin-3a treatment. In A, C & D: *P b 0.05 & **P b 0.01 versus cells traGAS5-mediated stimulation of cell death in response toUV-C irradiation
tended to be similar to that seen in the absence of exogenous apoptotic
stimuli, suggestive of an additive effect (rather than a synergistic effect)
of GAS5 on UV-C-induced cell death. Likewise, prior transfection of
22Rv1 cells clone 8 cells with GAS5 constructs tended to enhance
apoptosis (Fig. 3A & B) and decrease culture survival (Fig. 3C & D)
consequent upon treatment with the chemotherapeutic drugs,
nutlin-3a and docetaxel. Again the effect of each GAS5 construct was
additive to the effects of apoptotic stimuli on vector transfected cells.
Total cell number was also similar for cells transfected with GAS5
constructs and vector only in these experiments (Fig. 3E & F).
3.2. Survival correlates with GAS5 levels in stable clones of 22Rv1 cells
To examine if the basal survival of 22Rv1 clone 8 cells was related
to cellular GAS5 levels, cultures which had been transfected with the
pcDNA3/GAS5.AE construct or vector alone were subjected to selec-
tion with G418S, then ring-cloned to obtain stable clones. Of a total
of 15 different colonies which were picked from plates containingotherapeutic drugs. Cells were transfected with GAS5 constructs corresponding to ma-
, after 48 h, treated with either docetaxel (6 nM; n = 3) or nutlin-3a (10 μM; n = 4).
taining) and counting (nigrosin blue staining). A). Docetaxel-induced apoptosis is en-
imilar (but not statistically signiﬁcant) trend. C). Short-term culture viability is reduced
re viability is also reduced following transfection with GAS5 constructs and nutlin-3a
nd docetaxel treatment. F). Total cell number is normal following transfection with
nsfected with pcDNA3 alone (one-way ANOVA and Bonferrroni's MCT).
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whereas all 9 colonies of pcDNA3-transfected cells yielded actively
growing cultures; this high attrition rate of GAS5 stable clones is
consistent with the effects of GAS5 lncRNA on cell survival observed
in transient transfection experiments. The four GAS5 lncRNA stable
clones, along with an equivalent number of randomly selected vector
clones plus parental (untransfected) 22Rv1 clone 8 were then charac-
terized with respect to cellular GAS5 levels and basal survival. Cellular
levels of GAS5 lncRNA in stableGAS5 cloneswere approximately double
those of stable vector clones and untransfected cells (Fig. 4A). This had
no detectable effect on cell proliferation, as total cell number was simi-
lar in all groups (Fig. 4B). However, the proportionof apoptotic cellswas
clearly higher in stable GAS5 clones than in control groups (Fig. 4C), and
regression analysis of all data further revealed a direct relationship
between cellular GAS5 levels and the extent of apoptosis (Fig. 4D). In
agreement with these ﬁndings, the viability of stable GAS5 lncRNAFig. 4. The survival of 22Rv1 clone 8 cells stably expressing GAS5 lncRNA is related to cellular
mature GAS5 lncRNA (pcDNA3/GAS5.AE) or plasmid vector sequence alone (pcDNA3) were ob
(None), were plated at a ﬁxed density in the absence of G418S, and samples were taken at 24 h
A). GAS5 levels are increased in clones expressing the pcDNA3/GAS5.AE construct (n = 4 clone
cultures). B). Total cell number is similar in clones expressing the pcDNA3/GAS5.AE construct (
C). Apoptosis is higher in clones expressing the pcDNA3/GAS5.AE construct (n = 4 clones) t
cultures). D). Regression analysis of mean data from each clone and untransfected cells (n =
levels. E). Cell viability is reduced in clones expressing the pcDNA3/GAS5.AE construct (n = 4
cells (n = 3 cultures). F). Regression analysis of mean data from each clone and untransfected
cellular GAS5 levels. In A, C & E: *P b 0.05, **P b 0.01 & ***P b 0.001 versus pcDNA3-transfected
ANOVA and Bonferrroni's MCT).clones was reduced (Fig. 4E), and this parameter was inversely related
to cellular GAS5 lncRNA levels (Fig. 4F).
3.3. Transient expression of GAS5 also enhances basal apoptosis of PC-3
cells
To test the hypothesis that the pro-apoptotic effects of GAS5
lncRNA in prostate cells were not unique to the 22Rv1 cell line, the
effects of transient expression of the pcDNA3/GAS5.AE construct on
the survival of the metastatic cell line, PC-3, were examined. The basal
level of GAS5 transcripts was lower in PC-3 cells relative to 22Rv1
clone 8 cells (compare Figs. 5A and 1A), as previously reported [20],
and this basal level was enhanced approximately seven-fold upon
transfection with the pcDNA3/GAS5.AE plasmid (Fig. 5A). This
increased GAS5 lncRNA expression was accompanied by a doubling of
the basal apoptotic rate (Fig. 5B), and a decrease in short-term cultureGAS5 levels. Clones of 22Rv1 clone 8 cells stably expressing a plasmid construct encoding
tained by G418S selection and ring cloning. These, along with parental 22Rv1 clone 8 cells
, for assessment of GAS5 levels, and at 72 h, for assessment of apoptosis and cell survival.
s) relative to clones expressing vector alone (n = 4 clones) and untransfected cells (n = 3
n = 4 clones) or vector alone (n = 4 clones) and in untransfected cells (n = 3 cultures).
han in clones expressing vector alone (n = 4 clones) and in untransfected cells (n = 3
9) demonstrates that the level of basal apoptosis is directly proportional to cellular GAS5
clones) compared with clones expressing vector alone (n = 4 clones) and untransfected
cells (n = 9) demonstrates that the level of culture viability is indirectly proportional to
stable clones; ^P b 0.05 & ^^P b 0.01 versus untransfected 22Rv1 clone 8 cells (one-way
Fig. 5. Effect of GAS5 ncRNA on the basal survival of PC-3 cells. Cells (n = 3 cultures) were transfected with GAS5 constructs corresponding to mature lncRNA (exons 1–12; AE) or
empty pcDNA3 vector as control, re-plated at 24 h post-transfection, then cell survival was determined after a further 48 h culture. A). Cellular GAS5 levels, as determined by
RT-qPCR, are increased at 24 h post-transfection with the GAS5-encoding construct. B). The proportion of apoptotic cells is increased after transfection with GAS5. C). Total cell
number is normal after transfection with GAS5. D) Short-term culture viability is reduced after transfection with GAS5. In A, B & D: *P b 0.05 versus cells transfected with
pcDNA3 alone (unpaired Student's t-test).
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able (Fig. 5C). Thus increased expression of GAS5 lncRNA had similar
effects in both 22Rv1 clone 8 and PC-3 cells.
3.4. Down-regulation of GAS5 attenuates apoptosis in 22Rv1 clone 8 cells
As GAS5 levels are lower in prostate cell lines derived frommetasta-
seswhen comparedwith primary prostate tumors [20], and GAS5 levels
decline as LNCaP cells become castrate resistant in an in vivomodel [28],
it is important to determine the effect of down-regulating GAS5 levels
on prostate cell survival. For this, 22Rv1 clone 8 cells were transfected
with one of four different siRNAs which target different GAS5 se-
quences. All four siRNAs reduced the cellular GAS5 transcript level,
when compared with negative control siRNA; GAS5 siRNA #3 appeared
slightly less effective than the other GAS5 siRNAs (Fig. 6A). The basal
apoptotic rate appeared lower in cells transfected with GAS5 siRNAs,
with the exception of GAS5 siRNA #3 (Fig. 6B), consistent with its
reduced efﬁcacy in down-regulating cellular GAS5 levels (Fig. 6A). In-
deed, in siRNA-transfected cells, basal apoptosis was directly related
to cellular GAS5 levels (Fig. 6C), in agreement with ﬁndings from stable
clones of 22Rv1 cells (Fig. 4D). However, no statistically signiﬁcant
effects were detectable for total cell number (Fig. 6C), short-term
culture viability (Fig. 6D) or colony forming ability (Fig. 6E), and no sta-
tistically signiﬁcant relationships were observed between any of these
parameters and cellular GAS5 levels (data not shown). Thus, reductions
in GAS5 levels in actively growing 22Rv1 cells signiﬁcantly decrease the
basal apoptotic rate, but this is not accompanied by detectable changes
in overall cell survival parameters, presumably due to the low basal
apoptotic rate extant in control and siRNA-treated 22Rv1 cells (b4% in
all cultures examined: Fig. 6B & C).
In contrast, when the rate of apoptosis was increased by exposure to
UV-C irradiation, marked attenuations in apoptosis induction (Fig. 7A)
and the associated losses of culture viability (Fig. 7D) and colony
forming ability (Fig. 7F) were observed. In the short term, total cell
number was unaffected (Fig. 7C), suggesting that down-regulation of
GAS5 inhibits apoptosis induction but not growth arrest consequentupon UV-C irradiation (e.g. compare Figs. 7C & 6D). Statistically signiﬁ-
cant relationshipswere observed between cellular GAS5 levels immedi-
ately prior to UV-C irradiation and apoptosis (Fig. 7B), short-term
culture viability (Fig. 7E) and colony forming ability (Fig. 7G). Indeed,
short term experiments with GAS5 siRNAs #2 & #4, revealed that
reductions in cellular GAS5 levels diminished apoptosis induction and
loss of culture viability upon exposure to the chemotherapeutic drugs
docetaxel (Fig. 8A & C), nutlin-3a (Fig. 8E & G) and mitoxantrone
(Fig. 8I & K). Importantly, for each drug, both apoptosis and culture
viability were quantitatively related to cellular GAS5 levels [for
docetaxel (Fig. 8B &D); for nutlin-3a (Fig. 8F &H); and, formitoxantrone
(Fig. 8J & L)].
4. Discussion
This is the ﬁrst report demonstrating that the lncRNA-encoding
and snoRNA host gene, GAS5, negatively regulates the survival of
prostate cells. In these cells, high levels of GAS5 lncRNA expression
promote basal apoptosis and enhance the action of a range of apopto-
tic stimuli, whereas low levels, while having have no detectable effect
on basal survival, markedly attenuate the induction of programmed
cell death in response to physical and chemical stimuli, consistent
with previous studies in lymphoid cells [26,30] and in other epithelial
cell lines [18,20]. The current study further extends these ﬁndings by
demonstrating for the ﬁrst time in any cell type that cell death is
quantitatively related to cellular GAS5 levels, suggesting that GAS5
ncRNA may act as a ‘master regulator’ of this process.
Elevated levels of GAS5 lncRNA stimulated basal apoptosis in 22Rv1
cells and enhanced apoptosis induction by UV-C irradiation and drugs
in an additive manner, as previously noted for MCF7 and HEK 293T
cell lines [20]. Conversely, lowering the levels of GAS5 expression
dampened the cell death response to apoptotic stimuli, consistent
with observations in lymphoid cells, in which GAS5 siRNAs attenuate
both apoptosis induction by dexamethasone and the cytostatic effects
of rapamycin and other clinically important rapalogues [26,27,30]. On
the other hand, siRNA-mediated knockdown of GAS5 in HeLa cells had
Fig. 6. Effect of GAS5 siRNA on the basal survival of 22Rv1 clone 8 cells. Cells (n = 3 cultures) were transfected with one of four different siRNAs that target different GAS5
sequences (#1–4) or negative control (NC) siRNA. Cells were harvested at 72 h post-transfection, and replated for assessment of cell survival after a further 72 h. A). Cellular
GAS5 levels, as determined by RT-qPCR, are decreased at 72 h post-transfection with all four GAS5 siRNAs; of the two siRNAs that target exon 12, siRNA #3 is less effective than
siRNA #4. *P b 0.05 & ***P b 0.001 versus cells transfected with NC siRNA; ^P b 0.05 versus cells transfected with GAS5 #4 siRNA (one-way ANOVA and Bonferrroni's MCT). B). The pro-
portion of apoptotic cells at 72 h post-replating is decreased in cultures transfected with GAS5 siRNAs #1, #2 and #4. *P b 0.05 & **P b 0.01 versus cells transfected with NC siRNA
(one-way ANOVA and Dunnett's MCT). C). Apoptosis is related to GAS5 levels in siRNA transfected cells (n = 15). D). Total cell number at 72 h post-replating is normal.
E). Short-term viability at 72 h post-replating is normal. F). Colony formation in long-term clonogenic assays is also normal.
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ment, but it nevertheless potentiated dexamethasone-mediated inhibi-
tion of this process [18], indicating that in some cases the effects of
GAS5 on cell survival are cell- or stimulus-speciﬁc.
Nevertheless, the diverse nature of the apoptotic stimuli affected by
GAS5 silencing in 22Rv1 cells, which include a DNA damaging agent
(UV-C irradiation), a MDM2 inhibitor (nutlin-3a), a microtubule stabi-
lizing agent (docetaxel) and a topoisomerase II inhibitor/DNA intercalat-
ing agent (mitoxantrone), indicates that GAS5 participates in a late and
common step that mediates the activation of the apoptotic machinery
by these agents. Furthermore, for all stimuli, the extent of apoptosis in-
duction is clearly determined by the cellular level of GAS5 immediately
prior to their application. This observation, in particular, is reminiscent
of the action of established key apoptosis regulators, such as members
of the Bcl-2 family, for which the expression levels of pro- and anti-
apoptotic molecules are crucial in determining overall sensitivity to a
diverse range of death stimuli, including cytotoxic anti-cancer drugs
[31]. It will be important to investigate the functional relationships
connecting GAS5 with Bcl-2 family members and other prominent
regulators of sensitivity to apoptosis, such as the Inhibitor of Apoptosis
Protein (IAP) family [32].Under normal physiological conditions, apoptosis (along with cell
proliferation) serves to regulate tissue cell number, and consequently
defective apoptosis can underlie many important diseases, including
cancer, and key regulators of apoptosis are encoded by tumor sup-
pressor genes [33–35]. In addition, the action of many cancer chemo-
therapeutic agents is dependent upon the proper engagement of the
cellular apoptotic machinery, so that resistance to therapy is often
associated with defective apoptosis [31,32,34,36–38]. The present
ﬁndings, that GAS5 lncRNA regulates both basal apoptosis in prostate
cells and their survival upon exposure to a range of apoptotic stimuli,
may therefore have clinical signiﬁcance in relation to both prostate
oncogenesis and the response of prostate tumors to therapy. Though
clinical data are lacking in this area, experimental data link reduced
GAS5 expression and the development of prostate cancer to metastatic
disease [28]. Present ﬁndings further raise the possibility that reduced
GAS5 expression may contribute to the development of drug resistance
in metastatic disease. In addition, our observation that increased GAS5
levels in (metastasis-derived) PC-3 result in decreased survival (similar
to the response of 22Rv1 clone 8 cells), suggests that the mechanisms
that mediate GAS5 lncRNA action remain intact in metastatic prostate
cells. Therefore, enhancement of cellular GAS5 levels in prostate cancer
Fig. 7. Effect of GAS5 siRNA on the survival of 22Rv1 clone 8 cells after UV-C-induced apoptosis. Cells (n = 3 cultures) were transfected with one of four GAS5 siRNAs (#1–#4) or
negative control (NC) siRNA and, after 72 h, irradiated with UV-C light. A). Transfection of GAS5 siRNAs attenuates UV-C induced apoptosis at 48 h post-irradiation. B). Apoptosis is
related to cellular GAS5 levels prior to UV-C irradiation. C). Total cell number at 48 h post-irradiation is normal. D). Transfection of GAS5 siRNAs attenuates UV-C induced loss of
culture viability at 48 h post-irradiation. E). Culture viability is inversely related to cellular GAS5 levels prior to UV-C irradiation. F). Transfection of 22Rv1 cells with GAS5 siRNAs
prior to UV-C irradiation improves long term survival; an example image of clonogenic assay plates is shown on the right. G). Colony forming ability is related to cellular GAS5 levels
prior to UV-C irradiation. In A, D & F: *P b 0.05 & **P b 0.01 versus cells transfected with NC siRNA (one-way ANOVA and Dunnett's MCT).
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tic drugs may offer an improved therapeutic strategy.
GAS5 transcript levels are negatively controlled by the mTOR path-
way, so that cellular GAS5 levels can be raised through the use of
mTOR inhibitors [16,26,27]. The use of these inhibitors for the therapy
of castration-resistant prostate cancer has been advocated for other
reasons, notably because mTOR activity is upregulated in a large
proportion of advanced prostate tumors, mainly due to the loss of the
tumor suppressor PTEN and constitutive activation of Akt (e.g. see
[39,40]). Activation of this pathway has signiﬁcant, potentially
oncogenic, consequences [41,42], which include suppression of GAS5
lncRNA levels [26,27]. In experimental models including prostate cell
lines and xenografts, mTOR inhibitors have been shown to augment
the action of various drugs, including taxanes and anti-androgens
[39,40,43], but the possible involvement of GAS5 ncRNA in these bene-
ﬁcial effects has not previously been addressed.
Previous studies of epithelial cell lines from several laboratories,
have suggested that both snoRNA-containing GAS5 transcripts and
mature GAS5 lncRNA may be able to regulate apoptosis [18,20]. In the
present study, we therefore performed a side-by-side comparison of
the U74-containing GAS5-O1 EST, which among the various GAS5
ESTs studied to-date has potent apoptosis inducing activity [20,29],
and the mature GAS5 lncRNA, containing no snoRNA-encoding se-
quences. This comparison revealed similar potency for the two GAS5
ncRNA isoforms, suggesting that the pro-apoptotic activity resides
within exonic sequence which is common to both isoforms (i.e. exons
2–12; GAS5.AE contains no introns and so no snoRNAs).
Consistent with this, others have shown that a sequence derived
from exon 12 of GAS5 forms a hairpin structure that mimics the GRE
(GRE mimic or GREM) of glucocorticoid-responsive genes and thatcan bind to the DNA-binding domain of the glucocorticoid receptor
[18]. This results in suppression of glucocorticoid-mediated transcrip-
tional regulation of target genes, including anti-apoptotic cIAP2, in
epithelial cell lines [18]. Most signiﬁcantly in the current context,
GAS5 lncRNA binds to the corresponding domain on the androgen
receptor and inhibits transcriptional stimulation [18]. Given the central
role of the androgen receptor in the survival of prostate cancer cells
[44,45], this is potentially of great importance, since down-regulation
of GAS5 levels may allow increased pro-survival signalling through
the androgen receptor pathway. These observations open up new
therapeutic opportunities, as GAS5 lncRNA-based inhibition of andro-
gen receptor signalling has the potential to promote prostate cancer
cell death even when the pathway is activated through the appearance
of androgen receptor mutations, including truncated, constitutively
active variants, which have been recognized as an important focus for
the design of novel targeted therapies [44–46].
5. Conclusions
We have shown that GAS5 lncRNA is a key regulator of prostate cell
survival. Other recentwork has identiﬁed several other lncRNAs that act
in the opposite direction to control cell life/death decisions in prostate
cells. These include: prostate-speciﬁc transcript 1 (PCGEM1) [47]; pros-
tate cancer non-coding RNA 1 (encoded by PRNCR1) [48] and prostate
cancer associated transcript-1 (encoded by PCAT-1) [49], both of
which are located in the 8q24 ‘gene desert’ region; PlncRNA-1 [50];
and PCA3, which is encoded in antisense orientation within intron 6
of PRUNE2 [51]. All of these other lncRNAs are up-regulated in prostate
cancer and exert pro-survival effects on prostate cell lines, in direct
contrast to GAS5, which is pro-apoptotic. Together these ﬁndings
Fig. 8. Effect of GAS5 siRNA on the survival of 22Rv1 clone 8 cells after treatment with
chemotherapeutic drugs. Cells (n = 3 cultures) were transfected with one of two
GAS5 siRNAs (#2 & #4) or negative control (NC) siRNA and, after 72 h, replated then
treated with either docetaxel (6 nM), nutlin-3a (10 μM) or mitoxantrone (200 nM) for
48 h. A) Induction of apoptosis by docetaxel is reduced in GAS5 siRNA transfected cul-
tures. B). The extent of apoptosis is related to cellular GAS5 levels prior to initiation of
docetaxel treatment. C) Cells transfected with GAS5 siRNAs exhibit increased viability
after docetaxel treatment. D). Viability is related to cellular GAS5 levels prior to initiation
of docetaxel treatment. E) Induction of apoptosis by nutlin-3a is reduced in GAS5 siRNA
transfected cultures. F). The extent of apoptosis is related to cellular GAS5 levels prior to
initiation of nutlin-3a treatment. G) Cells transfected with GAS5 siRNAs exhibit increased
viability after nutlin-3a treatment. H). Viability is related to cellular GAS5 levels prior to
initiation of nutlin-3a treatment. I) Induction of apoptosis by mitoxantrone is reduced in
GAS5 siRNA transfected cultures. J). The extent of apoptosis is related to cellular GAS5
levels prior to initiation ofmitoxantrone treatment. K) Cells transfectedwith GAS5 siRNAs
exhibit increased viability after mitoxantrone treatment. L). Viability is related to cellular
GAS5 levels prior to initiation of mitoxantrone treatment. In A, C, E, G, I & K: *P b 0.05 &
**P b 0.01 versus cells transfected with NC siRNA (one-way ANOVA and Dunnett's MCT).
1622 M.R. Pickard et al. / Biochimica et Biophysica Acta 1832 (2013) 1613–1623underscore the importance of lncRNAs in prostate cancer and
demonstrate that lncRNAs can regulate cell survival both positively,
i.e. suppressing cell death, and negatively, i.e. promoting cell death,
suggesting a key role for these newly discovered molecular regulators.
Better understanding of the mechanism(s) by which such lncRNAs
regulate cell survival will undoubtedly assist the design of optimized
targeted therapies in the future.
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